Talaris Therapeutics Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 4

Employees

  • Latest Deal Type
  • M&A

Talaris Therapeutics General Information

Description

Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.

Contact Information

Formerly Known As
Regenerex
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 300 East Market Street
  • Suite 350
  • Louisville, KY 40202
  • United States
+1 (502)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Vertical(s)
Corporate Office
  • 300 East Market Street
  • Suite 350
  • Louisville, KY 40202
  • United States
+1 (502)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Talaris Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 19-Oct-2023 Completed Generating Revenue
8. IPO 07-May-2021 Completed Generating Revenue
7. Later Stage VC (Series B) 30-Sep-2020 Completed Clinical Trials - Phase 3
6. Later Stage VC (Series A) 18-Apr-2019 Completed Clinical Trials - Phase 3
5. Grant 01-Jan-2012 Completed Clinical Trials - Phase 3
4. Grant 01-Jan-2011 Completed Clinical Trials - Phase 3
3. Grant 01-Jan-2008 Completed Clinical Trials - Phase 3
2. Grant 01-Jan-2005 $1.61M Completed Clinical Trials - Phase 3
1. Grant 01-Jan-2004 $441K Completed Clinical Trials - Phase 3
To view Talaris Therapeutics’s complete valuation and funding history, request access »

Talaris Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A-1
Series A 40,000,000 $0.000100 $1 $1 1x $1 20.73%
To view Talaris Therapeutics’s complete cap table history, request access »

Talaris Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies
Biotechnology
Louisville, KY
4 As of 2023

Austin, TX
 

Oklahoma City, OK
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Talaris Therapeutics Competitors (30)

One of Talaris Therapeutics’s 30 competitors is Rein Therapeutics, a Formerly VC-backed company based in Austin, TX.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Rein Therapeutics Formerly VC-backed Austin, TX
Tetherex Pharmaceuticals Venture Capital-Backed Oklahoma City, OK
Pharmacyclics Venture Capital-Backed San Francisco, CA
OrphoMed Venture Capital-Backed San Francisco, CA
Verastem Formerly VC-backed Needham, MA
You’re viewing 5 of 30 competitors. Get the full list »

Talaris Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Talaris Therapeutics Former Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aisling Capital Venture Capital Minority
BlackRock Asset Manager Minority
Citadel Enterprise Americas Hedge Fund Minority
Cormorant Asset Management PE/Buyout Minority
Eventide Asset Management Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Talaris Therapeutics Acquisitions (1)

Talaris Therapeutics’s most recent deal was a Reverse Merger with Tourmaline Bio. The deal was made on 19-Oct-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Tourmaline Bio 19-Oct-2023 Reverse Merger Drug Discovery
To view Talaris Therapeutics’s complete acquisitions history, request access »

Talaris Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

34.39 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Talaris Therapeutics’s complete esg history, request access »

Talaris Therapeutics FAQs

  • When was Talaris Therapeutics founded?

    Talaris Therapeutics was founded in 2002.

  • Where is Talaris Therapeutics headquartered?

    Talaris Therapeutics is headquartered in Louisville, KY.

  • What is the size of Talaris Therapeutics?

    Talaris Therapeutics has 4 total employees.

  • What industry is Talaris Therapeutics in?

    Talaris Therapeutics’s primary industry is Biotechnology.

  • Is Talaris Therapeutics a private or public company?

    Talaris Therapeutics is a Private company.

  • What is Talaris Therapeutics’s current revenue?

    The current revenue for Talaris Therapeutics is .

  • How much funding has Talaris Therapeutics raised over time?

    Talaris Therapeutics has raised $365M.

  • Who are Talaris Therapeutics’s investors?

    Aisling Capital, BlackRock, Citadel Enterprise Americas, Cormorant Asset Management, and Eventide Asset Management are 5 of 13 investors who have invested in Talaris Therapeutics.

  • Who are Talaris Therapeutics’s competitors?

    Rein Therapeutics, Tetherex Pharmaceuticals, Pharmacyclics, OrphoMed, and Verastem are some of the 30 competitors of Talaris Therapeutics.

  • When was Talaris Therapeutics acquired?

    Talaris Therapeutics was acquired on 19-Oct-2023.

  • Who acquired Talaris Therapeutics?

    Talaris Therapeutics was acquired by Tourmaline Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process